Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke


Opinion statement

Stroke is the most common cause of disability and a major cause of mortality. Each year, more than 500,000 Americans sustain a stroke. Reperfusion and antithrombotic therapies are still of limited benefit, hence increasing interest has been focused on therapeutic approaches that prevent and/or modulate infarct evolution. Hyperglycemia in acute stroke has a poor prognosis and is associated with significant morbidity and mortality. However, it remains unclear whether intensive lowering of blood glucose levels in the hyperacute and acute phases of stroke improves clinical outcomes. Experimental data suggest that elevated blood glucose may contribute to infarct expansion directly through a number of maladaptive metabolic pathways and that treatment with insulin may attenuate these adverse effects. Despite some controversy surrounding the optimal level of blood glucose control, much of the evidence to date supports rigorous blood glucose control and comprehensive cardiovascular risk factor management to prevent stroke in patients with diabetes. The current recommendation is to aim for strict control of blood pressure, glucose, and lipids along with lifestyle modification to improve cardiovascular health. However, there remains a distinct paucity of information concerning secondary stroke prevention. To date, the overwhelming evidence suggests that aggressive glucose management should be the standard of care in all patients with stroke and hyperglycemia. This article presents an overview of the recommendations for the optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    National Diabetes Information Clearinghouse (NDIC): National diabetes statistics, 2007. Available at http://www.diabetes.niddk.nih.gov/DM/PUBS/statistics. Accessed March 2009.
  2. 2.
    Howard G, Bergman R, Wagenknecht LE, et al.; Insulin Resistance Atherosclerosis Study (IRAS) Investigators: Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the “minimal model”. Ann Epidemiol 1998, 8:358–369.PubMedCrossRefGoogle Scholar
  3. 3.
    Saydah S, Miret M, Sung J, et al.: Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24:1397–1402.PubMedCrossRefGoogle Scholar
  4. 4.
    Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 25:1157–1164.Google Scholar
  5. 5.
    Boden-Albala B, Cammack S, Chong J, et al.: Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events. Diabetes Care 2008, 31:1132–1137.PubMedCrossRefGoogle Scholar
  6. 6.
    The ACCORD Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.CrossRefGoogle Scholar
  7. 7.
    Idris I: Safety of very tight glucose control in type 2 diabetes in question diabetes, obesity and metabolism. Diabetes Obes Metab 2008, 10:438–440.PubMedCrossRefGoogle Scholar
  8. 8.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591.PubMedCrossRefGoogle Scholar
  9. 9.
    The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572.CrossRefGoogle Scholar
  10. 10.
    Goldstein LB, Adams R, Becker K, et al.: Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32:280–299.PubMedGoogle Scholar
  11. 11.
    UK Prospective Diabetes Study Group: Intensive blood-glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  12. 12.
    National Heart, Lung, and Blood Institute: For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease [press release]. Available at http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. Accessed March 2009.
  13. 13.
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  14. 14.
    UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854–865.CrossRefGoogle Scholar
  15. 15.
    Riddle M, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080–3086.PubMedCrossRefGoogle Scholar
  16. 16.
    Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716–1730.PubMedCrossRefGoogle Scholar
  17. 17.
    Gilmore RM, Stead LG: The role of hyperglycemia in acute ischemic stroke. Neurocrit Care 2006, 5:153–158.PubMedCrossRefGoogle Scholar
  18. 18.
    Furie K, Inzucchi SE: Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Curr Neurol Neurosci Rep 2008, 8:12–19.PubMedCrossRefGoogle Scholar
  19. 19.
    Matthews DR, Holman R: UKPDS 30 year data—are there legacy effects of improved glucose and blood pressure control? Presented at the 44th Annual Meeting of the European Association for the Study of Diabetes. Rome, Italy; September 7–11, 2008.Google Scholar
  20. 20.
    Levetan CS: Effect of hyperglycemia on stroke outcomes. Endocr Pract 2004, 10(Suppl 2):34–39.PubMedGoogle Scholar
  21. 21.
    Myint PK, Sinha S, Wareham NJ, et al.: Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship? Stroke 2007, 38:271–275.PubMedCrossRefGoogle Scholar
  22. 22.
    Mellbin LG, Malmberg K, Norhammar A, et al.: DIGAMI 2 Investigators: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008, 29:166–176.PubMedCrossRefGoogle Scholar
  23. 23.
    Lapcevic M, Vukovic M, Dimitrijevic I, et al.: The effect of medicamentous and non-medicamentous therapy on lowering risk factors for cardiovascular and cerebrovascular episodes in an interventional study [in Serbian]. Srp Arh Celok Lek 2007, 135:554–561.PubMedCrossRefGoogle Scholar
  24. 24.
    Kunte H, Schmidt S, Eliasziw M, et al.: Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007, 38:2526–2530.PubMedCrossRefGoogle Scholar
  25. 25.
    Mazzone T: Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Am J Med 2007, 120(Suppl 2):S26–S32.PubMedCrossRefGoogle Scholar
  26. 26.
    Sobel BE: Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 2007, 120(Suppl 2):S3–S11.PubMedCrossRefGoogle Scholar
  27. 27.
    Ivey FM, Ryan AS, Hafer-Macko CE, et al.: Treadmill aerobic training improves glucose tolerance and indices of insulin sensitivity in disabled stroke survivors: a preliminary report. Stroke 2007, 38:2752–2758.PubMedCrossRefGoogle Scholar
  28. 28.
    The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464–1476.CrossRefGoogle Scholar
  29. 29.
    Ligaray KP, Isley WL: Diabetes mellitus, type 2-endocrinology. Emedicine website. http://emedicine.medscape.com. Accessed August 6, 2008.
  30. 30.
    Votey SR, Peters AL: Diabetes mellitus, type 2—a review—emergency medicine. Emedicine website. http://emedicine.medscape.com. Accessed July 9, 2008.
  31. 31.
    Lamb WH: Diabetes mellitus, type 1—pediatrics: general medicine. Emedicine website. http://emedicine.medscape.com. Accessed October 19, 2007.
  32. 32.
    British National Formulary: BNF 57. Available at http://www.bnf.org/bnf/index.htm. Accessed March 2009.
  33. 33.
    National Institute for Health and Clinical Excellence: Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline 66. Available at http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf. Accessed March 2009.
  34. 34.
    Munro N, Feher MD: Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes. Br J Gen Pract Vol. 58:531–533.Google Scholar
  35. 35.
    Jiang WJ: Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 2008, 373:341–344.PubMedCrossRefGoogle Scholar
  36. 36.
    Nayagam VM, Wang X, Tan YC, et al.: SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006, 11:959–967.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.School of Medicine, Health Policy and PracticeUniversity of East AngliaNorfolkUK

Personalised recommendations